Shibo Jiang, MD, PhD, New York Blood Center

Shibo Jiang, MD, PhD
Shibo Jiang, MD, PhD

The research focus of the Jiang and Lanying Du, PhD laboratories is on the development of antiviral therapeutic agents and vaccines for the treatment and prevention of HIV infection/AIDS and other emerging and remerging infectious diseases caused by severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and influenza viruses, as well as the blood transfusion-related viruses, including Zika virus (ZIKV) and West Nile virus (WNV).



  1. Yuxian He, Hong Lu, Pamela Siddiqui, Yusen Zhou and Shibo Jiang. Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Contains Multiple Conformation-Dependent Epitopes that Induce Highly Potent Neutralizing Antibodies. J Immunol. April 15, 2005, 174 (8) 4908-4915; DOI:
  2. Yuxian He, Jingjing Li, Wenhui Li, Sara Lustigman, Michael Farzan and Shibo Jiang. Cross-Neutralization of Human and Palm Civet Severe Acute Respiratory Syndrome Coronaviruses by Antibodies Targeting the Receptor-Binding Domain of Spike Protein. J Immunol. May 15, 2006, 176 (10) 6085-6092; DOI:
  3. Lanying Du, Yuxian He, Yusen Zhou, Shuwen Liu, Bo-Jian Zheng, Shibo Jiang. The spike protein of SARS-CoV â?? a target for vaccine and therapeutic development. Nat Rev Microbiol. March 2009, 7 (3) 226-236. DOI:10.1038/nrmicro2090.
  4. Lanying Du, Guangyu Zhao, Chris C.S Chan, Shihui Sun, Min Chen, Zhonghua Liu, Hongxiang Guo, Yuxian He, Yusen Zhou, Bo-Jian Zheng, Shibo Jiang. Recombinant Receptor-Binding Domain of SARS-CoV Spike Protein Expressed in Mammalian, Insect and E. Coli Cells Elicits Potent Neutralizing Antibody and Protective Immunity. Virology. October 2009, 393 (1) 144-150. DOI: 10.1016/j.virol.2009.07.018.
  5. Lanying Du, Guangyu Zhao, Lin Li, Yuxian He, Yusen Zhou, Bo-Jian Zheng, Shibo Jiang. Antigenicity and Immunogenicity of SARS-CoV S Protein Receptor-Binding Domain Stably Expressed in CHO Cells. Biochem Biophys Res Commun. July 2009, 384 (4) 486-490. DOI: 10.1016/j.bbrc.2009.05.003.
  6. Lanying Du, Lei Jin, Guangyu Zhao, Shihui Sun, Junfeng Li, Hong Yu, Ye Li, Bo-Jian Zheng, Robert C Liddington, Yusen Zhou, Shibo Jiang. Identification and Structural Characterization of a Broadly Neutralizing Antibody Targeting a Novel Conserved Epitope on Influenza H5N1 Hemagglutinin. J Virol. February 2013, 87 (4) 2215-2225; DOI: 10.1128/JVI.02344-12.
  7. Lanying Du, Cuiqing Ma, Shibo Jiang. Antibodies Induced by Receptor-Binding Domain in Spike Protein of SARS-CoV do not Cross-Neutralize the Novel Human Coronavirus HCoV-EMC. J Infect. October 2013, 67 (4) 348-350. DOI: 10.1016/j.jinf.2013.05.002.
  8. Shibo Jiang, Lanying Du, Yusen Zhou. Influenza Hemagglutinin-Specific Monoclonal Antibodies for Preventing and Treating Influenza Virus Infection. U.S. Patent No. US 8,900,585 B2. December 02, 2014.